We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

AnaSpec Offers Beta-Amyloid (1-40) and (1-42) Peptides

Read time: Less than a minute

AnaSpec, EGT Group has provided a whole suite of reagents for the advancement of Alzheimer’s disease (AD) research.

From peptides to assay kits to antibodies to dyes, AnaSpec is the trusted source of integrated proteomics solutions for AD research.

Amongst the more than 300 β-amyloid peptides, we offer β-amyloid (1-40) and (1-42) that are HFIP treated.

β-amyloids are amphiphilic peptides with a hydrophilic N-terminal domain (residues 1 to 28) and a hydrophobic C-terminal (residues 29 to 40-42), the latter corresponding to a part of the transmembrane domain of APP.

β-Amyloid assembly into fibrils is initiated by a conformational transition from random coil to β-sheet (hence the name β-amyloid) and a nucleation-dependent aggregation process.

Aβ peptides that are 39 to 42 amino acid residues in length with a molecular mass of approximately 4 kDa are the core components of neuritic plaques seen in Alzheimer’s disease (AD) brains.

Studies have found that dissolving in HFIP favors alpha helical structure and tends to be monomeric.

HFIP treatment of lyophilized Aβ-peptide results in a dense, homogeneous preparation of unaggregated peptide and samples can be stored as peptide films.

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.